News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
123
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

123 matching headlines

Main company stories
Clear
Latest

finance.yahoo.com Analyst action

Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgradesโ€”Which Pharma Stock Has More Upside?

Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)'s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm's logic in each case was based on a comparable set of factors: pipelines that the market appears to undervalue, and valuations โ€ฆ

Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
Just inNext headlines
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum

AbbVie and BioLabs University of Toronto are partnering to support the next generation of biotechnology innovators in Ontario. Two winning companies will each receive a year of laboratory space and access to equipment at no cost, as well as access to support and mentorship. โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign

AbbVie introduces Birdies for Brain Health, a purpose-driven PGA TOUR campaign that turns birdies into awareness and support for people living with brain health conditions and their care partners Birdies for Brain Health will debut at the 2026 Presidents Cup with donations to six โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie (ABBV) Advances While Market Declines: Some Information for Investors

In the latest close session, AbbVie (ABBV) was up +1.78% at $261.70. This change outpaced the S&P 500's 0.48% loss on the day. At the same time, the Dow lost 0.29%, and the tech-heavy Nasdaq lost 0.56%. The drugmaker's stock has climbed by 3.07% โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVieโ€™s Latest Migraine Success Strengthens its Growth Story

AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is a diversified pharmaceutical company that provides stable cash flows through its โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

If you're not familiar with Israel "Izzy" Englander, you might want to be. He's the founder of the Millennium Management hedge fund -- and a billionaire, suggesting that his fund has done quite well. Indeed, the company recently sported a valuation near $100 billion, โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

Is AbbVie Stock Actually Overpriced?

Photo by jarmoluk on Pixabay AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual migraine is a recurrent and debilitating form of migraine associated with attacks โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
seekingalpha.com Capital return Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie declares $1.73 dividend

* AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) declares $1.73/share quarterly dividend [https://seekingalpha.com/pr/20647654-abbvie-declares-quarterly-dividend], in line with previous. * Forward yield [https://seekingalpha.com/symbol/ABBV/dividends/yield?source=news_bullet] 2.74% * Payable Nov. 16; for shareholders of record Oct. 15; ex-div Oct. 15. * See ABBV Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/ABBV/dividends?source=news_bullet] MORE ON โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Capital return Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable November 16, 2026, to stockholders of record at the close of business โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Gains as Qulipta Opens a New Migraine Market

This article first appeared on GuruFocus. AbbVie (NYSE:ABBV), the global immunology and pharmaceutical company, said Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine. Shares traded at $252.25 Thursday morning, up approximately 0.4%. Warning! GuruFocus has detected 5 Warning Signs โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments explode. Choosing between AbbVie Inc (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) requires weighing diversification against specialized growth. AbbVie is a broad biopharmaceutical giant with a diverse โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

Although AbbVie ABBV boasts a wide range of products across various therapeutic segments, immunology remains its most important driver of top-line growth. The company's immunology franchise has been firing on all cylinders, driven by the continued strength of Skyrizi and Rinvoq. In the first โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Menstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability2,4 Atogepant demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

Is AbbVie (ABBV)โ€™s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference

Key Points Interested in AbbVie Inc.? Here are five stocks we like better. SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note

AbbVie (ABBV) closed the most recent trading day at $248.78, moving -2.99% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca

Company Logo Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovation Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines. AbbVie has successfully diversified its portfolio beyond its historic blockbuster Humira, while Pfizer โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie ABBV reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatment with three major drug classes. The study is investigating etentamig, an investigational BCMA โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVieโ€™s Humira Cash Cow Is Shrinkingโ€”Can Its Dividend Keep Growing?

Quick Read ABBV boosted its quarterly dividend 5.5% to $1.73 even as Humira sales collapsed 36%, sustained by $17.8 billion in annual free cash flow. Skyrizi and Rinvoq are replacing Humira's lost revenue, but Skyrizi faces its own patent expiry in 2033, setting up โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma

AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie (ABBV)โ€™s Blood Cancer Success Adds Weight to its Pipeline Story

AbbVie Inc. (NYSE:ABBV)'s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial's main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Touts Positive Data For Multiple Myeloma Drug

AbbVie Inc.(NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The study demonstrated that the drug outperformed standard therapies, meeting its primary goals for objective response rate and progression-free survival. โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Capital return Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?

Photo by jarmoluk on Pixabay A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability. For an investor focused on cash returns, how much โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?

AbbVie's ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since mid-June.Zacks Investment Research Image Source: Zacks Investment Research Trading above both key moving averages is typically considered a bullish technical signal, suggesting favorable short- and long-term momentum. However, โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies Etentamig demonstrated low rates of cytokine release syndrome (CRS) โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Completes Acquisition of Apogee Therapeutics

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time. A live audio webcast of โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

SkinMedicaยฎ Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks1 SkinMedicaยฎalso introduces HA5ยฎHydra Collagen Facial Mist for easy, on-the-go hydration IRVINE, Calif., Sept. 1, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

NORTH CHICAGO, Ill., Aug. 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time. A live audio webcast of the โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Balance sheet Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?

What AbbVie's Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi's role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether to buy AbbVie Inc (NYSE:ABBV) or Eli Lilly and Co (NYSE:LLY) requires weighing different growth engines. Both companies operate in the same general space but offer โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

AbbVie ABBV announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking approval for its blockbuster immunology drug, Skyrizi (risankizumab), for subcutaneous (SC) induction in adult patients with moderately to severely active Crohn's disease (CD). If approved, adult patients โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026
finance.yahoo.com Regulatory and legal Main company ๐Ÿ‡ฒ๐Ÿ‡ฝ Mexico

AbbVie (ABBV) Filed For EU Crohn's Disease Label Expansion

AbbVie (NYSE: ABBV) has submitted a regulatory application to the European Medicines Agency for SKYRIZI (risankizumab) subcutaneous induction in adults with moderately to severely active Crohn's disease. The filing seeks to add a less invasive induction treatment option to AbbVie's Crohn's disease portfolio in โ€ฆ

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +4.8% ABBV stored weekly price path from 19 Sep 2025 to 11 Sep 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context